GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and our regulatory and manufacturing expertise. GW’s research explores the potential therapeutic application of cannabinoids and we have evaluated the pharmacology of a number of cannabinoids across a wide range of disease areas.
Our primary focus is on disorders of the central nervous system (CNS) including epilepsy. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (delta-9-tetrahydrocannibinol and cannabidiol), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States.
We have a deep pipeline of additional cannabinoid product candidates which include compounds in development for epilepsy, glioma and schizophrenia.
GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.
Sativex® (delta-9-tetrahydrocannibinol and cannabidiol)
Sativex® is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
To find an overview of our product development pipeline, please follow the below link: